Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INGAP Peptide and Ustekinumab in Type 1 Diabetes
NCT02204397Phase 2Completed
- Sponsor
- Jewish General Hospital
- Start
- Nov 2015
- Primary completion
- Mar 2017
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of INGAP peptide, ustekinumab in type 1 diabetes mellitus (T1D), sponsored by Jewish General Hospital. Started Nov 2015; status: completed.
02
Drugs
INGAP peptideustekinumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02204397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204397.